The Quantellect read.As of Nov 19, 2026, 4 active firms cover OUTLOOK THERAPEUTICS INC: 2 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. The target range is very wide, $1.00 to $10.50 (about 10.5x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $4.28 sits 944% above the current $0.41. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.05 next quarter toward $-0.12 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Neutral
Strong Buy00%
Buy250%
Neutral250%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$4.28
+944.5% upside
Average target across 4 active firms as of Nov 19, 2026 vs $0.41 current
Highest Target$10.50
Average Target$4.28
Lowest Target$1.00
Detailed analyst forecasts for OTLK
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 2 of 4 active firms rate OTLK a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
OTLK EPS & revenue forecast
EPS · NEXT QUARTER
$-0.05
Range $-0.08 – $-0.01 · 3 analysts · -79% YoY
Next period, 3 analysts expect OUTLOOK THERAPEUTICS INC to earn $-0.05 a share (range $-0.08 – $-0.01), versus $-0.22 a year earlier. Full-year consensus is $-0.43, growing to $-0.12 the year after.
REVENUE · NEXT QUARTER
$5.3M
Range $1.3M – $8.9M · 3 analysts · -539% YoY
Revenue is expected to reach $5.3M (range $1.3M – $8.9M), -539.1% year-over-year., rising to $44.1M next year.
Top analysts covering OUTLOOK THERAPEUTICS INC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OTLK.
#1
Daniil Gataulin
Chardan Capital · Rank #51
Neutral
$1.00+144.3% to target
Overall win rate
52%
+ Follow
#2
Julian Harrison
BTIG · Rank #183
Buy
$4.00+877.3% to target
Overall win rate
41%
+ Follow
#3
Douglas Tsao
HC Wainwright & Co. · Rank #312
Neutral
$1.60+290.9% to target
Overall win rate
35%
+ Follow
#4
Edward Woo
Ascendiant Capital · Rank #570
Buy
$10.50+2465.4% to target
Overall win rate
24%
+ Follow
#5
EH
Eddie Hickman
Guggenheim
Neutral
No targeton OTLK
Coverage
—
+ Follow
OTLK stock forecast FAQ
What is OTLK's average 12-month price target?+
The 4 active firms with a live target average $4.28 for OUTLOOK THERAPEUTICS INC over the next 12 months, ranging from a $10.50 high to a $1.00 low, as of Nov 19, 2026.
Is OTLK stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 4 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for OTLK?+
The Street-high target is $10.50 (Ascendiant Capital), and the Street-low is $1.00 (Chardan Capital). The average of all 4 active-firm targets is $4.28.
How many active Wall Street firms cover OTLK?+
4 active firms have a recognized rating on OUTLOOK THERAPEUTICS INC as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering OTLK?+
Among analysts who currently cover OTLK, Daniil Gataulin of Chardan Capital has the strongest overall Quantellect track record (Rank #51). Their current call is Neutral with a $1.00 target.
What is OUTLOOK THERAPEUTICS INC's projected EPS for next quarter?+
The consensus estimate is $-0.05 per share (range $-0.08 – $-0.01) across 3 analysts. Full-year EPS is projected at $-0.43, rising to $-0.12 the following year.
How much revenue is OUTLOOK THERAPEUTICS INC expected to report next quarter?+
Consensus revenue is $5.3M (range $1.3M – $8.9M). Full-year revenue is projected at —, growing to $44.1M next year.
Have analysts been upgrading or downgrading OTLK lately?+
As of Nov 19, 2026, 2 of 4 active firms rate OTLK a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OTLK calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.